急性淋巴细胞白血病，2021年第2.2版，美国国立综合癌症网络（NCCN）肿瘤学临床实践指南

Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

作者信息

Brown Patrick A, Shah Bijal, Advani Anjali, Aoun Patricia, Boyer Michael W, Burke Patrick W, DeAngelo Daniel J, Dinner Shira, Fathi Amir T, Gauthier Jordan, Jain Nitin, Kirby Suzanne, Liedtke Michaela, Litzow Mark, Logan Aaron, Luger Selina, Maness Lori J, Massaro Stephanie, Mattison Ryan J, May William, Oluwole Olalekan, Park Jae, Przespolewski Amanda, Rangaraju Sravanti, Rubnitz Jeffrey E, Uy Geoffrey L, Vusirikala Madhuri, Wieduwilt Matthew, Lynn Beth, Berardi Ryan A, Freedman-Cass Deborah A, Campbell Mallory

机构信息

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Moffitt Cancer Center.

出版信息

J Natl Compr Canc Netw. 2021 Sep 20;19(9):1079-1109. doi: 10.6004/jnccn.2021.0042.

DOI:10.6004/jnccn.2021.0042

PMID:34551384

Abstract

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk assessment and stratification for risk-adapted therapy; treatment strategies for Philadelphia chromosome (Ph)-positive and Ph-negative ALL for both adolescent and young adult and adult patients; and supportive care considerations. Given the complexity of ALL treatment regimens and the required supportive care measures, the NCCN ALL Panel recommends that patients be treated at a specialized cancer center with expertise in the management of ALL This portion of the Guidelines focuses on the management of Ph-positive and Ph-negative ALL in adolescents and young adults, and management in relapsed settings.

摘要

美国国立综合癌症网络（NCCN）急性淋巴细胞白血病（ALL）指南聚焦于基于免疫表型以及细胞遗传学/分子标志物对ALL亚型进行分类；针对风险适应性治疗的风险评估与分层；青少年、年轻成人及成年患者中费城染色体（Ph）阳性和Ph阴性ALL的治疗策略；以及支持性护理考量。鉴于ALL治疗方案的复杂性以及所需的支持性护理措施，NCCN ALL专家组建议患者应在对ALL管理具有专业知识的专科癌症中心接受治疗。本指南的这一部分聚焦于青少年和年轻成人中Ph阳性和Ph阴性ALL的管理以及复发情况下的管理。